Don’t Buy Merck... Buy this “Trifecta” Stock Instead

You’re receiving this email as part of your subscription to Andrew Zatlin’s Moneyball Daily [Unsubscribe]( [Moneyball Economics] Don’t Buy Merck… Buy this “Trifecta” Stock Instead Tuesday, October 25, 2022 Cold and flu season is here. But for every cough, sneeze, and sniffle, there’s a healthcare stock on the rise. Here are some stocks to keep your portfolio healthy… even if you aren’t. [CLICK HERE TO LAUNCH VIDEO OR READ THE FULL TRANSCRIPT BELOW »»]( > ADVERTISEMENT < Millionaire Investor Reveals: "How I Made My Second Fortune... By Avoiding 99% of Stocks" Buy this small group of unique stocks... never sell them... and make all the money you need... No matter what happens in the market. [Revealed here: the name and ticker of the #1 stock.]( For a transcript of this video, see below. This transcript has been lightly edited for length and clarity. Don’t Buy Merck… Buy this “Trifecta” Stock Instead Healthcare is an amazing investment sector. No matter what’s happening with the markets or economy, people need healthcare. Furthermore, the isolation we’ve faced the past few years has weakened our immune systems. We weren’t exposed to the common cold or flu! And now that we’re back in the world, we’re catching germs left and right — it’s cold and flu season times ten! This is bad news for anyone hoping to stay healthy during the holidays. But it’s great news for healthcare companies… Healthcare Companies are Hiring Payroll data from this sector is already hitting record levels. Take a look: So far in 2022, the healthcare sector has added more jobs than in any full year in the past decade. And we’ve still got a few months of the year to go. A boost in hiring means an industry poised for growth… It also means investors like us need to jump in! But where should we invest? After all, healthcare is a massive industry. And not every company in this sector is sitting pretty. To identify the most promising opportunities, I use hiring data. Let me show you… Three Promising Stocks Here’s recent hiring data for Baxter (NYSE: BAX). Baxter makes products that treat kidney disease and other chronic medical conditions: Look at its hiring — up and to the right. It’s the same deal with Gilead Sciences (Nasdaq: GILD): And Quest Diagnostics (NYSE: DGX): These companies are reporting strong hiring, and some of them are also producing solid dividends. Gilead’s dividends add up to more than four percent. And Baxter’s are at three percent. At a time when the overall stock market is struggling, these payouts can provide some welcomed cash in your pocket. Focus on the Ones with Upside But not every healthcare stock is a “buy” right now. For example: Here’s a recent chart from big pharma company Merck (NYSE: MRK): This company’s hiring is up. But so is its stock price! In my opinion, much of its potential upside is already baked in. Now compare that to Quest: This one’s taken a dive recently, but now it’s starting to creep back up. (Maybe people are looking at my hiring data, eh?) This stock has plenty of room to run! An Investment Trifecta Bottom line: the right healthcare stocks can offer an investment trifecta: - Recession-proof demand. - Strong dividends. - Plenty of room for growth. Are you a “Pro” subscriber? If so, check out my #1 healthcare stock to scoop up now. In the meantime, Zatlin out. FOR MONEYBALL PRO READERS ONLY > [LEARN MORE]( < In it to win it, [Andrew Zatlin] Andrew Zatlin Moneyball Economics Copyright 2022 © Moneyball Economics, All rights reserved. You signed up on []( Our mailing address is: Moneyball Economics 201 International Circle Suite 110 Hunt Valley, MD 21030 [Update Subscription Preferences]( | [Unsubscribe from this list]( | [Terms & Privacy]( RISK NOTICE: All investing comes with risk. That includes the investments teased in this letter. You should never invest more than you can afford to lose. Please use this research for the purpose that it's intended — as research only. You should consult a professional financial advisor before ever taking a position in any securities you see herein. SECURITY HOLDING NOTICE: Although we are never compensated from any companies for coverage, you should be aware that Moneyball Economics, its authors, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. While authors might actively transact in the securities mentioned, they will always have a net position that is consistent with the position set forth in our research reports, letters and updates. DISCLAIMERS: The work included in this communication is based on diverse sources including SEC filings, current events, interviews, corporate press releases, and information published on funding platforms, but the views we express and the conclusions we reach are our own. As such, this content may contain errors, and any investments described in this content should be made only after reviewing the filings and/or financial statements of the company, and only after consulting with your investment advisor. Actual results may differ significantly from the results described herein. Furthermore, nothing published by Moneyball Economics, Inc should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. Moneyball Economics is an independent provider of education, information and research on publicly traded companies, and as such, it accepts no direct or indirect compensation from any companies or third parties mentioned in any of our letters, reports or updates